| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Killer Cells, Natural | 22 | 2025 | 334 | 4.080 |
Why?
|
| Tumor Microenvironment | 6 | 2025 | 626 | 2.080 |
Why?
|
| Myeloid-Derived Suppressor Cells | 4 | 2021 | 50 | 2.000 |
Why?
|
| Neoplasms | 10 | 2025 | 2847 | 1.630 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2025 | 858 | 1.610 |
Why?
|
| Interleukin-7 | 2 | 2025 | 45 | 1.060 |
Why?
|
| Interleukin-12 | 12 | 2021 | 121 | 0.990 |
Why?
|
| Immunological Synapses | 1 | 2025 | 32 | 0.920 |
Why?
|
| Interferon-gamma | 13 | 2017 | 518 | 0.910 |
Why?
|
| Receptors, Immunologic | 1 | 2025 | 118 | 0.900 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 294 | 0.650 |
Why?
|
| T-Lymphocytes | 5 | 2021 | 1706 | 0.590 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2025 | 930 | 0.560 |
Why?
|
| Lymphocyte Activation | 5 | 2017 | 672 | 0.550 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 32 | 0.530 |
Why?
|
| Cell Line, Tumor | 10 | 2025 | 3483 | 0.490 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 555 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 8 | 2017 | 987 | 0.410 |
Why?
|
| Antineoplastic Agents | 8 | 2011 | 1757 | 0.350 |
Why?
|
| Mice | 18 | 2025 | 17574 | 0.300 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 2 | 2019 | 15 | 0.290 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2005 | 96 | 0.280 |
Why?
|
| Animals | 19 | 2025 | 33114 | 0.260 |
Why?
|
| Cytokines | 4 | 2005 | 1312 | 0.230 |
Why?
|
| Chemokines | 3 | 2019 | 128 | 0.220 |
Why?
|
| Receptors, Fc | 3 | 2017 | 29 | 0.210 |
Why?
|
| Humans | 27 | 2025 | 126020 | 0.210 |
Why?
|
| Trastuzumab | 8 | 2017 | 145 | 0.210 |
Why?
|
| Cell Survival | 1 | 2025 | 841 | 0.200 |
Why?
|
| ErbB Receptors | 1 | 2004 | 285 | 0.190 |
Why?
|
| Neuroblastoma | 2 | 2019 | 537 | 0.190 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 9 | 0.180 |
Why?
|
| Receptors, Interleukin-12 | 3 | 2008 | 9 | 0.180 |
Why?
|
| K562 Cells | 2 | 2019 | 95 | 0.180 |
Why?
|
| Receptors, IgG | 3 | 2008 | 56 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2019 | 678 | 0.170 |
Why?
|
| Oncolytic Viruses | 1 | 2021 | 75 | 0.160 |
Why?
|
| Breast Neoplasms | 4 | 2021 | 2583 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2019 | 457 | 0.160 |
Why?
|
| Oncolytic Virotherapy | 1 | 2021 | 89 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2020 | 62 | 0.150 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2019 | 258 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2020 | 105 | 0.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 165 | 0.150 |
Why?
|
| Adenoviridae | 1 | 2021 | 573 | 0.140 |
Why?
|
| Immunoglobulin G | 5 | 2015 | 763 | 0.140 |
Why?
|
| Ligands | 1 | 2019 | 477 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2011 | 539 | 0.130 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2017 | 109 | 0.130 |
Why?
|
| Signal Transduction | 4 | 2025 | 4471 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 7 | 2011 | 987 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 710 | 0.110 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 282 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2020 | 741 | 0.110 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 269 | 0.110 |
Why?
|
| Receptors, Interleukin | 2 | 2005 | 33 | 0.110 |
Why?
|
| CD3 Complex | 3 | 2004 | 89 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2017 | 331 | 0.100 |
Why?
|
| DNA-Binding Proteins | 5 | 2005 | 1889 | 0.100 |
Why?
|
| Trans-Activators | 4 | 2003 | 674 | 0.100 |
Why?
|
| Cancer Vaccines | 2 | 2004 | 188 | 0.090 |
Why?
|
| Adenocarcinoma | 2 | 2011 | 976 | 0.090 |
Why?
|
| Female | 15 | 2021 | 67877 | 0.090 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2011 | 19 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2006 | 1302 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 686 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2005 | 1095 | 0.080 |
Why?
|
| STAT4 Transcription Factor | 3 | 2008 | 9 | 0.080 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 2 | 2005 | 6 | 0.070 |
Why?
|
| Inositol Polyphosphate 5-Phosphatases | 2 | 2005 | 6 | 0.070 |
Why?
|
| Transcriptome | 1 | 2015 | 1060 | 0.070 |
Why?
|
| Antibodies, Neoplasm | 2 | 2006 | 56 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2005 | 1593 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 251 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2008 | 582 | 0.070 |
Why?
|
| CD56 Antigen | 2 | 2004 | 26 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2008 | 84 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2006 | 638 | 0.070 |
Why?
|
| Flow Cytometry | 3 | 2004 | 758 | 0.070 |
Why?
|
| Membrane Microdomains | 1 | 2008 | 59 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 2 | 2006 | 380 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2005 | 1540 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 3 | 2003 | 985 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 6 | 2005 | 4488 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2005 | 336 | 0.060 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2005 | 17 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2004 | 749 | 0.060 |
Why?
|
| Interleukins | 1 | 2006 | 119 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2005 | 123 | 0.060 |
Why?
|
| Interferon-alpha | 2 | 2005 | 235 | 0.060 |
Why?
|
| Monokines | 1 | 2004 | 2 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2005 | 135 | 0.060 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2004 | 9 | 0.060 |
Why?
|
| Chemokine CCL4 | 1 | 2004 | 13 | 0.060 |
Why?
|
| CpG Islands | 1 | 2005 | 332 | 0.050 |
Why?
|
| Transfection | 1 | 2005 | 945 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 105 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2004 | 180 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 422 | 0.050 |
Why?
|
| STAT1 Transcription Factor | 4 | 2005 | 69 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 1294 | 0.050 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2003 | 32 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2004 | 222 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 781 | 0.050 |
Why?
|
| Time Factors | 4 | 2005 | 6006 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 1225 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2002 | 90 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 788 | 0.040 |
Why?
|
| Single-Chain Antibodies | 1 | 2021 | 36 | 0.040 |
Why?
|
| Shock | 1 | 2002 | 96 | 0.040 |
Why?
|
| Escherichia coli Infections | 1 | 2002 | 183 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2021 | 229 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 229 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2005 | 3704 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 125 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2017 | 2389 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2003 | 745 | 0.040 |
Why?
|
| Genotype | 1 | 2004 | 2601 | 0.040 |
Why?
|
| Sepsis | 1 | 2002 | 487 | 0.030 |
Why?
|
| Macrophages | 1 | 2002 | 633 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 64 | 0.030 |
Why?
|
| Feeder Cells | 1 | 2016 | 8 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 2016 | 35 | 0.030 |
Why?
|
| Blood Component Removal | 1 | 2016 | 35 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 4406 | 0.030 |
Why?
|
| Monocytes | 1 | 2017 | 331 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2006 | 360 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2004 | 4914 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 400 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2005 | 12310 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2005 | 2898 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 361 | 0.020 |
Why?
|
| Interleukin-2 | 2 | 2004 | 234 | 0.020 |
Why?
|
| Mice, Transgenic | 3 | 2003 | 2311 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1002 | 0.020 |
Why?
|
| Aged | 3 | 2005 | 19973 | 0.020 |
Why?
|
| Spleen | 2 | 2003 | 251 | 0.020 |
Why?
|
| Mice, SCID | 2 | 2003 | 567 | 0.020 |
Why?
|
| Middle Aged | 3 | 2005 | 27300 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 414 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1937 | 0.020 |
Why?
|
| Adult | 3 | 2005 | 30235 | 0.020 |
Why?
|
| Cell Line | 2 | 2004 | 2562 | 0.020 |
Why?
|
| Male | 3 | 2021 | 62050 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 826 | 0.020 |
Why?
|
| Syk Kinase | 1 | 2008 | 17 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 85 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 118 | 0.020 |
Why?
|
| Genomics | 1 | 2015 | 1570 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 220 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 352 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2006 | 56 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 330 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2006 | 61 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2006 | 59 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 2318 | 0.010 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2005 | 22 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 475 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 200 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2004 | 42 | 0.010 |
Why?
|
| Inositol Phosphates | 1 | 2004 | 12 | 0.010 |
Why?
|
| Cholesterol | 1 | 2008 | 538 | 0.010 |
Why?
|
| L-Selectin | 1 | 2004 | 19 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 578 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2004 | 100 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 2004 | 37 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2005 | 230 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 363 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2003 | 37 | 0.010 |
Why?
|
| Measles virus | 1 | 2003 | 16 | 0.010 |
Why?
|
| Vaccines, Combined | 1 | 2003 | 39 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 573 | 0.010 |
Why?
|
| Chromium | 1 | 2002 | 7 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2003 | 151 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 182 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 292 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 437 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 648 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 2003 | 240 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 66 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2003 | 180 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 236 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2002 | 64 | 0.010 |
Why?
|
| Etoposide | 1 | 2002 | 109 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 610 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2002 | 116 | 0.010 |
Why?
|
| Cell Movement | 1 | 2006 | 846 | 0.010 |
Why?
|
| Acute-Phase Proteins | 1 | 2002 | 42 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2002 | 131 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 73 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 719 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 336 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 727 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2002 | 286 | 0.010 |
Why?
|
| Methotrexate | 1 | 2002 | 312 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 420 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2002 | 439 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 1596 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 460 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 2553 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 3603 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 2059 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2002 | 755 | 0.010 |
Why?
|
| Apoptosis | 1 | 2002 | 1805 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 6543 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 1494 | 0.010 |
Why?
|